NCT06777628 Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
| NCT ID | NCT06777628 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Liver Cancer, Adult |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-15 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-15 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years * diagnosis of HCC * execution of laboratory tests and subsequent treatments and follow-up at our center. * obtained written informed consent to the study participation Exclusion Criteria: * immune-related concomitant diseases * HIV infection
Contact & Investigator
Laura Gramantieri
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06777628 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cancer, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06777628 currently recruiting?
Yes, NCT06777628 is actively recruiting participants. Contact the research team at laura.gramantieri@aosp.bo.it for enrollment information.
Where is the NCT06777628 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06777628 clinical trial?
NCT06777628 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Laura Gramantieri at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.